Cancer drug development faces a crucial bottleneck: proving new treatments work better often requires waiting years or decades for survival data. This challenge has become particularly acute in chronic lymphocytic leukemia, where recent therapies keep patients progression-free for 6-9 years, making traditional clinical trials impractically long. A promising solution may lie in measurable residual disease testing, which detects microscopic cancer remnants in blood samples. When patients achieve undetectable levels below one cancer cell per 10,000 normal cells (uMRD4), this marker strongly predicts long-term outcomes. Multiple clinical trials now demonstrate that patients reaching this threshold after fixed-duration treatments experience significantly longer progression-free survival. The FDA recognizes surrogate endpoints that can reasonably predict clinical benefit, and mounting evidence suggests uMRD4 meets this standard. For patients, this could mean faster access to breakthrough therapies. Instead of waiting nearly a decade to prove a new treatment extends survival, regulators could approve drugs based on their ability to eliminate detectable disease within months. This represents a fundamental shift from measuring how long treatments work to measuring how completely they work. The approach could transform oncology drug development beyond blood cancers. However, validation remains critical - the marker must consistently predict outcomes across different treatment mechanisms and patient populations. Current efforts focus on establishing uMRD4 as an accelerated approval pathway specifically for treatment-naive chronic lymphocytic leukemia patients receiving time-limited therapies, potentially setting precedent for broader applications in cancer medicine.